In the race to develop more drugs, the pharmaceutical industry may actually be wasting a lot of money for clinical trial procedures that are not absolutely necessary. In fact, data gathered from roughly 25 percent of procedures administered to patients are not only unnecessary, but can also be traced to as much as $5 billion in overall trial costs each year, according to a new study.
